Skip to contentC
CRISPR Therapeutics AG
C
CRSPCRISPR Therapeutics AG Q2 2026 · 10-Q
Revenue$10.18M$10.18M+1,041.4% vs Q2 2025 Net Income-$91.15M-$91.15MN/M vs Q2 2025 EPS Diluted-$0.94-$0.94N/M vs Q2 2025 Operating Income-$117,269,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CRISPR Therapeutics AG · CIK 1674416 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$84,146,000N/M Margins · derivedOperating margin-1151.8%+24557.1 pt vs Q2 2025
Net margin-895.3%+22484.6 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 3, 2026 · 34 d after period end